Formulations of cross-linkable polymers capable of forming non-toxic and biocompatible hydrogels in situ containing at least one of doxycycline or minocycline. Methods of using the hydrogels for treating the skin or ocular tissues of mammals exposed to vesicant compounds such as sulfur mustard (SM) nitrogen mustard (NM) or half mustard (2-chloroethyl ethyl sulfide (CEES)) are also disclosed.

Use of A-ring aromatized acetyl minocycline compounds (I) for treating T cell-mediated diseases is claimed. Use of A-ring aromatized acetyl minocycline compounds of formula (I) for treating T cell-mediated diseases is claimed. R1-R5 : acetyl or H where at least one of R1-R5 is acetyl. An independent claimS included for a pharmaceutical composition comprising A-ring aromatized acetyl minocycline compounds (I) and a pharmaceutical acceptable carrier. [Image] ACTIVITY : Antiallergic; Immunosuppress...

Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide e.g. large cell lymphoma or restenosis are treated with a thioredoxin reductase inhibitor e.g. auranofin or arsenic trioxide and a nitric oxide donating compound e.g. isosorbide mononitrite or isosorbide dinitrite or nitroglycerin or S-nittrosothiol. Patients having a disease associated with nitric oxide synthase overexpression or increased activity e.g. Parkinson's disease or se...

Topical minocycline compositions with reduced fluorescence are provided. In some instances the compositions include an amount of a minocycline active agent associated with porous calcium particles. Also provided are methods of using the compositions e.g. in the treatment of acne.

The present invention provides combinations of an antipsychotic drug and a tetracycline particularly minocycline for the treatment of psychotic disorders particularly schizophrenia. The invention also provides formulations wherein the release of one or both of the antipsychotic drug and the tetracycline is modified. The invention also provides methods using the combined therapy for treatment of psychotic disorders particularly schizophrenia comprising an antipsychotic drug and a tetracycline.